* Drug fails in one trial, succeeds in another
* To continue another follow-on trial
* Sucampo shares up 8 pct
July 21 (Reuters) - Sucampo Pharmaceuticals Inc and a unit of Japan's Takeda Pharmaceutical said two identical late-stage trials of their experimental drug for opioid-induced bowel dysfunction (OBD) showed mixed results, with one study meeting the main goal and the other failing.
The study named OBD0631 met the main goal of showing a statistically significant change in the frequency of spontaneous bowel movements at the eighth week of treatment when the drug, lubiprostone, was compared to a dummy drug.
However, another trial, named OBD0632, failed to achieve the same goal.
Sucampo will continue another follow-on safety study in 445 patients who would receive one 24-mcg gel capsule of lubiprostone twice a day for nine months. It expects data from this study in late 2009.
If the follow-on study is successful, Sucampo expects to submit the data to U.S. health regulators in 2010.
Sucampo shares were up 8 percent at $7.00 in trading after the bell. They closed at $6.50 Tuesday on Nasdaq.
(Reporting by Esha Dey in Bangalore; Editing by Vinu Pilakkott) Keywords: SUCAMPO/ (esha.dey@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: esha.dey.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* To continue another follow-on trial
* Sucampo shares up 8 pct
July 21 (Reuters) - Sucampo Pharmaceuticals Inc and a unit of Japan's Takeda Pharmaceutical said two identical late-stage trials of their experimental drug for opioid-induced bowel dysfunction (OBD) showed mixed results, with one study meeting the main goal and the other failing.
The study named OBD0631 met the main goal of showing a statistically significant change in the frequency of spontaneous bowel movements at the eighth week of treatment when the drug, lubiprostone, was compared to a dummy drug.
However, another trial, named OBD0632, failed to achieve the same goal.
Sucampo will continue another follow-on safety study in 445 patients who would receive one 24-mcg gel capsule of lubiprostone twice a day for nine months. It expects data from this study in late 2009.
If the follow-on study is successful, Sucampo expects to submit the data to U.S. health regulators in 2010.
Sucampo shares were up 8 percent at $7.00 in trading after the bell. They closed at $6.50 Tuesday on Nasdaq.
(Reporting by Esha Dey in Bangalore; Editing by Vinu Pilakkott) Keywords: SUCAMPO/ (esha.dey@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: esha.dey.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.